How can we help you?

CORPORATE HEADQUARTERS

Biogen Inc.
225 Binney Street
Cambridge, MA 02142
USA

Biogen Corporate Contacts

INTERNATIONAL HEADQUARTERS

(Europe & Canada)
Biogen International GmbH
Neuhofstrasse 30
6340 Baar
Switzerland

Media

EU Media Enquiries
publicaffairs.eu@biogen.com

U.S. Public Affairs/Media
+1 781 464 3260
public.affairs@biogen.com

Investors

Visit our Investors page for financial information and reporting.

Investor Relations
+1 781 464 2442
IR@biogen.com

If you experience any side effects from a Biogen product, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly to your national Health Authority (HA):

• United Kingdom: via the Yellow Card Scheme or search for MHRA Yellow Card on the Google Play or Apple App Store
• Ireland: visit www.hpra.ie or email medsafety@hpra.ie

By reporting side effects, you help provide more information on the safety of this medicine.

Biogen UK & Ireland – Contact Information

If you would like to ask a medical information question, report a side effect, or a product complaint, please contact Biogen:

For biosimilar products: UK 0800 008 7401 | IRE 1800 812 719 | Email: Medinfo.europe@biogen.com

For all other products: UK 0800 008 7401 | IRE 1800 812 719 | Email: MedInfoUKI@biogen.com  

To meet our ethical and regulatory obligations, we may need to contact you for further details. For reports made to us, we are obliged to store certain details about you (the reporter), the patient (if different) and information relevant to the side effect, and to share required details with regulatory agencies globally. Please refer to Biogen’s Privacy Policy for further information.

Why reporting possible side effects matters

Patient safety is our highest priority. Biogen has an ethical and regulatory responsibility to continually assess and communicate the benefit–risk profile of our products to patients, healthcare professionals and regulators.

We collect safety information from patients, caregivers and healthcare professionals, and may conduct post‑marketing studies to evaluate long‑term effects. Our safety and benefit‑risk management team reviews information from all sources (foreign, domestic, clinical trials, published literature and post‑marketing) and determines what actions may be needed. When a potential safety issue is identified, we seek more information, report our findings to regulatory agencies, and update product labelling and other communications as appropriate.

Note: Biogen markets Biosimilar products pursuant to an agreement with Samsung Bioepis, the marketing authorisation holder for such products. If you report an Adverse Event (AE) / Product Complaint (PC) for any of these products, your report will be sent to Samsung Bioepis, who may follow-up with you if they require further information regarding your AE or PC.

If you wish to report any compliance concerns regarding Biogen or any of its employees or contractors, you may do so in writing at the address provided below or confidentially and anonymously, by using the Compliance Helpline.

To submit a report through the Compliance Helpline, click here for international Compliance Helpline dial-in numbers.

Click here to submit a report online, or write to us at:

Compliance
Biogen International GmbH
Neuhofstrasse 30
6340 Baar
Switzerland